Earnings call transcript: Cavco Industries Q3 2025 beats expectations
Cavco Industries (NASDAQ:CVCO), maintaining a "GOOD" financial health score according to InvestingPro analysis, reported ...
Investor's Business Daily on MSN32m
Stock Market Today: Dow Jones Falls As Trump Tariff Deadline Looms; Nvidia Slips As MicroStrategy Makes This Move (Live Coverage)
The Fed's preferred inflation gauge, the personal consumption and expenditures index, rose 0.3% from November and 2.6% on an ...
Nasdaq Composite clings to gain as tariff worries weigh on U.S. stocks
Tariff worries were weighing on the U.S. stock market Friday afternoon, with the Nasdaq Composite clinging to gains while the S&P 500 and Dow Jones Industrial Average fell. “I did not expect President ...
24/7 Wall St. on MSN59m
Nasdaq Composite Live: Apple (AAPL) Leads Tech Stocks Higher to End the Week
The big market story today is Apple (Nasdaq: AAPL), which is lifting all boats and driving the Nasdaq Composite over 1% ...
JPMorgan is deeply skeptical of Wall Street's upbeat reaction to Tesla's earnings miss
"The move higher in Tesla shares bore no relation whatsoever to the company's financial performance in the quarter," JPMorgan ...
Evercore ISI maintains Apple stock outperform with $260 target
Evercore ISI reiterated its positive stance on Apple stock (NASDAQ:AAPL), maintaining an Outperform rating and a price target of $260. The firm's analysis followed Apple's recent financial results, ...
MicroStrategy Preferred Stock Had to Be Sold At a Discount. You Won’t Believe the Yield Now.
The shares, the first preferred stock issue by the largest corporate holder of Bitcoin, didn’t get as strong a reception as ...
MicroStrategy Prices Preferred Stock Offering At $80 Per Share, Seeks $563M To Buy Bitcoin
MicroStrategy (NASDAQ:MSTR) continues its bold Bitcoin strategy with a new $563.4 million preferred stock offering, signaling unwavering confidence in the apex crypto. The company announced on Friday ...
Hosted on MSN2h
ETFs in Focus Post Intel's Q4 Earnings Beat
Intel INTC reported strong fourth-quarter 2024 results, beating estimates on both earnings and revenues. However, the chipmaker offered a downbeat outlook for the ongoing quarter. See the Zacks ...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.